Video

Baricitinib shows potential as lupus treatment

Publish date: June 15, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Wallace DJ et al. Ann Rheum Dis. 2018;77(Suppl 2):59. Abstract OP0019.

Pages

Recommended Reading

Caution crucial for stem cell transplant in scleroderma, despite potential interest
MDedge Rheumatology
Don’t trust interface dermatitis to diagnose dermatomyositis
MDedge Rheumatology
Median time to progression from discoid to systemic lupus may be less than a year
MDedge Rheumatology
Timely dermatomyositis diagnosis, treatment remain elusive
MDedge Rheumatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Rheumatology
Idiopathic pulmonary fibrosis a ‘robust diagnosis’
MDedge Rheumatology
Cutaneous lupus: Switching antimalarials can delay immunosuppressive therapy
MDedge Rheumatology
Long-term follow-up most important for hydroxychloroquine retinal screening
MDedge Rheumatology
Pemphigus remission rate tops 80% with rituximab
MDedge Rheumatology
EULAR scientific program highlights spectrum of translational research
MDedge Rheumatology